RNAC earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -1.40. Updated 2026-07-23.
Cartesian Therapeutics (RNAC) Research Hub
Cartesian Therapeutics (RNAC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 6.28 USD (+1.62%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.40, market cap 0.24B. This hub links to the full technical, earnings and options research available for RNAC.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.28 USD (+1.62%) |
| 52-week range | 6.01 USD – 11 USD |
| Trend regime | Range |
| 14-day RSI | 40.9 (Bearish) |
| Trailing P/E | -1.40 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for RNAC
Covered Call on RNAC: how it works, illustrative setup around the real 6.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RNAC: how it works, illustrative setup around the real 6.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RNAC: how it works, illustrative setup around the real 6.28 USD price, max profit/loss, breakeven and when to use it. Educational.
RNAC technical analysis: range, last 6.28 USD, RSI 40.9, 52w range 6.01 USD–11 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RNAC in?
Cartesian Therapeutics (RNAC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RNAC in an uptrend or downtrend?
As of 2026-10-26, RNAC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RNAC's trailing P/E ratio?
RNAC's trailing P/E is -1.40, with a market cap of 0.24B. See the earnings research page for full valuation detail.
When does RNAC next report earnings?
RNAC is next scheduled to report earnings on 2026-08-06.